Ocugen completes OCU400 Phase 3 enrollment, shares trade in tight NASDAQ range

By Thomas Klein, Operations & Strategy desk. Reviewed prior to publication on 2026-06-23, 16:32.

Ocugen Inc (US67577C1053) draws attention after completing patient enrollment in its Phase 3 liMeliGhT study for the OCU400 gene therapy candidate, while the shares continue to trade on NASDAQ around 1.30 US dollars per share according to recent price data.

What Reuters and others report

Ocugen announced that enrollment is now complete for the OCU400 Phase 3 liMeliGhT clinical trial in inherited retinal diseases, positioning the biotech to move toward top-line data and a potential biologics license application if results are positive, as highlighted in recent market commentary that cites the company’s update.TrendSpider overview citing the Phase 3 enrollment

The company, which focuses on gene therapies for blindness diseases, has described OCU400 as a modifier gene therapy designed to address multiple retinal conditions linked to different genetic mutations, an approach that could broaden its addressable patient base compared with mutation-specific treatments if efficacy and safety are confirmed in Phase 3.

Tuesday focus on analyst and technical signals

On the technical side, Ocugen shares recently closed at about 1.30 US dollars on NASDAQ, up roughly 4.8 percent on the previous session, with trading tools highlighting that the stock sits between a support zone around 1.16 dollars and resistance near 1.43 dollars, defining a relatively tight trading corridor in the near term.TradingKey technical analysis for OCGN

Recent technical screens classify the momentum picture as mixed but constructive, with several short- and medium-term moving averages generating buy signals while others flag caution, and a momentum ranking that places Ocugen in the mid-field of the broader biotechnology and medical research peer group on some platforms.Investing.com technical indicator summary for Ocugen

The gene therapy focus

Ocugen’s pipeline centers on ophthalmic gene therapies, with OCU400 targeting inherited retinal diseases such as retinitis pigmentosa and Leber congenital amaurosis, while additional candidates like OCU410 are being developed for conditions including dry age-related macular degeneration according to the company’s pipeline overview.Ocugen pipeline and program descriptions

Where the shares trade now

The Ocugen shares (US67577C1053) most recently traded on NASDAQ at 1.30 US dollars as of 2026-06-22, 16:00 Eastern Time.

This article is for informational purposes only and does not constitute investment advice or a solicitation to buy or sell any securities. All data were obtained from sources believed to be reliable but cannot be guaranteed.